SAB4504246
Anti-phospho-IRAK1 (pThr209) antibody produced in rabbit
affinity isolated antibody
Sinónimos:
Anti-IRAK, Anti-pelle
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
Productos recomendados
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
76 kDa
species reactivity
human
concentration
~1 mg/mL
technique(s)
ELISA: 1:40000
western blot: 1:500-1:1000
NCBI accession no.
UniProt accession no.
application(s)
research pathology
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
phosphorylation (pThr209)
Gene Information
human ... IRAK1(3654)
General description
Interleukin 1 receptor associated kinase 1 (IRAK1) is a serine/threonine kinase encoded by the gene with 14 exons mapped to human chromosome xq28. The encoded protein belongs to the IRAK family. IRAK1is characterized with a death domain at its N-terminal end which is involved in protein interaction.
Immunogen
The antiserum was produced against synthesized peptide derived from human IRAK1 around the phosphorylation site of Thr209.
Immunogen Range: 175-224
Immunogen Range: 175-224
Application
Anti-phospho-IRAK1 (pThr209) antibody produced in rabbit has been used in immunoprecipitation assay.
Biochem/physiol Actions
Interleukin 1 receptor associated kinase 1 (IRAK1) is a vital element of the interleukin-1 receptor (IL-1R) signaling pathway. IRAK1 functions as a downstream effector molecule of the toll like receptor (TLR) signaling pathway, implicated in inflammation, autoimmunity and cancer. IRAK1 is associated with systemic lupus erythematosus (SLE) and it is overexpressed in various cancer types including lung cancer. IRAK1, is considered to be a potential therapeutic target in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), triple-negative breast cancer (TNBC) metastasis and paclitaxel resistance. Increased expression of IRAK1 leads to head and neck squamous cell carcinomas (HNSCCs). Therefore, inhibition of IRAK1 might be a new therapeutic strategy in HNSCC.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Storage Class
10 - Combustible liquids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Yosuke Tanaka et al.
Nature communications, 13(1), 271-271 (2022-01-14)
Leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) are quiescent, insensitive to BCR-ABL1 tyrosine kinase inhibitors (TKIs) and responsible for CML relapse. Therefore, eradicating quiescent CML LSCs is a major goal in CML therapy. Here, using a G0 marker
Baohuan Cai et al.
Molecular cancer, 20(1), 165-165 (2021-12-16)
Stem Cell leukemia/lymphoma syndrome (SCLL) presents as a myeloproliferative disease which can progress to acute myeloid leukemia and is associated with the coincident development of B-cell and T-cell lymphomas. SCLL is driven by the constitutive activation of fibroblast growth factor
IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Allie K Adams et al.
Oncotarget, 6(41), 43395-43407 (2015-11-04)
The chromatin-binding DEK protein was recently reported to promote the growth of HPV+ and HPV- head and neck squamous cell carcinomas (HNSCCs). Relevant cellular and molecular mechanism(s) controlled by DEK in HNSCC remain poorly understood. While DEK is known to
Xiuling Zhang et al.
International journal of clinical and experimental pathology, 7(11), 8096-8104 (2015-01-01)
The interleukin-1 receptor associated kinases 1 (IRAK1) is a down stream effector molecule of the toll like receptor (TLR) signaling pathway, which is involved in inflammation, autoimmunity and cancer. However, the role of IRAK1 in lung cancer remains unclarified. Herein
Detlef Neumann et al.
Biochemical and biophysical research communications, 354(4), 1089-1094 (2007-02-06)
Ligand binding in the Toll-like/interleukin-1 receptor family results in the recruitment of an intracellular signaling complex. IRAK-1, which is centrally involved in this complex, is able to homo-oligomerize and to bind to Tollip and the adapters MyD88 and IRAK-4. The
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico